- Home
- SONN vs ENVB Comparison
SONN vs ENVB Comparison
Compare SONN & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- ENVB
- Stock Information
- Founded
- SONN N/A
- ENVB 1994
- Country
- SONN United States
- ENVB United States
- Employees
- SONN N/A
- ENVB N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- ENVB Health Care
- Exchange
- SONN Nasdaq
- ENVB Nasdaq
- Market Cap
- SONN 3.8M
- ENVB 3.1M
- IPO Year
- SONN N/A
- ENVB N/A
- Fundamental
- Price
- SONN $1.11
- ENVB $1.25
- Analyst Decision
- SONN Strong Buy
- ENVB Strong Buy
- Analyst Count
- SONN 1
- ENVB 1
- Target Price
- SONN $20.00
- ENVB $10.00
- AVG Volume (30 Days)
- SONN 46.3K
- ENVB 221.4K
- Earning Date
- SONN 08-13-2025
- ENVB 08-11-2025
- Dividend Yield
- SONN N/A
- ENVB N/A
- EPS Growth
- SONN N/A
- ENVB N/A
- EPS
- SONN N/A
- ENVB N/A
- Revenue
- SONN $1,000,000.00
- ENVB N/A
- Revenue This Year
- SONN $5,376.22
- ENVB N/A
- Revenue Next Year
- SONN N/A
- ENVB N/A
- P/E Ratio
- SONN N/A
- ENVB N/A
- Revenue Growth
- SONN 978.39
- ENVB N/A
- 52 Week Low
- SONN $1.08
- ENVB $1.01
- 52 Week High
- SONN $10.02
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- SONN 38.81
- ENVB 44.38
- Support Level
- SONN $1.11
- ENVB $1.18
- Resistance Level
- SONN $1.25
- ENVB $1.30
- Average True Range (ATR)
- SONN 0.06
- ENVB 0.07
- MACD
- SONN 0.00
- ENVB 0.02
- Stochastic Oscillator
- SONN 0.00
- ENVB 38.89
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.